Leadership 301 study

What we are studying

The purpose of this research study is to compare the effects (good and bad) of two dose levels of AQX-1125 (active study drug) to placebo (inactive study drug) in order determine which dose works best, how well the study drug is tolerated and how safe the study drug is in the treatment of Interstitial Cystitis and/or Bladder Pain Syndrome.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 80

Eligibility Criteria

  • Diagnosed with Interstitial Cystitis

What is involved

  • Oral study medication
  • ECG
  • Ophthalmologic exam

Compensation

45 per visit to site or to ophthalmologist

Contact Information

Study Coordinator
Janet Shuping
Email
jshuping@wakehealth.edu
Phone
336-716-2612
Principal Investigator
Robert J. Evans, M.D.

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.